EZH2 and neoplasm: Liquid biopsies: Circulating tumor DNA (ctDNA) from plasma or cerebrospinal fluid (CSF) can detect epigenetic changes (e.g., MGMT methylation, EZH2 amplification) that predict resistance (Mansouri et al., 2019).